According to previous studies, elevated XIAP levels may result from the activity of the AKT pathway (94), suggesting that CLL cells in the bone marrow may have elevated XIAP levels through the activation of the AKT pathway in response to venetoclax, mediating drug resistance. The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.